Dianthus Therapeutics (DNTH) Interest Expenses (2017 - 2025)

Dianthus Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $127.5 million for Q4 2025.

• On a quarterly basis, Interest Expenses rose 42615.67% year-over-year to $127.5 million in Q4 2025; TTM through Dec 2025 was $127.5 million, a 63873.5% increase from a year earlier, with the FY2025 full-year figure at $127.5 million, down 29.77% from the prior year.
• Interest Expenses improved to $127.5 million in Q4 2025 per DNTH's latest filing, from $126.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $127.5 million in Q4 2025 and bottomed at -$300000.0 in Q4 2024.
• The 5-year median for Interest Expenses is $7.7 million (2022), against an average of $24.4 million.
• Across the five-year window, Interest Expenses sank 99.96% in 2023 and jumped 855560.0% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $5.2 million in 2021, then soared by 107.39% to $10.8 million in 2022, then fell by 27.93% to $7.8 million in 2023, then plunged by 103.86% to -$300000.0 in 2024, then surged by 42615.67% to $127.5 million in 2025.
• Per Business Quant, the three latest DNTH Interest Expenses figures stand at $127.5 million (Q4 2025), $126.2 million (Q3 2025), and $15.5 million (Q2 2025).